Transitory deficit in high-density lipoproteins and apolipoprotein A-I.
Legras
B
B
Clerc
C
C
Ruelland
A
A
Doualin
G
G
Fertil
V
V
Cloarec
L
L
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A / Q000172:deficiency*; D001629:Bezafibrate / Q000009:adverse effects / Q000627:therapeutic use; D002995:Clofibric Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D058607:Fibric Acids; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008075:Lipoproteins, HDL / Q000172:deficiency*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000009:adverse effects / Q000627:therapeutic use
D016632:Apolipoprotein A-I; D001054:Apolipoproteins A; D058607:Fibric Acids; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; D002995:Clofibric Acid; C019304:ciprofibrate; D011341:Probucol; D001629:Bezafibrate